nature.com search

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

nature
search

Search My Account Login

advanced

where the list of authors contains where the title contains

Refine your results by…

volume

start page / article no.

Filters

Filter By:

Article type

Check one or more article types to show results from those article types only.

Amendments and Corrections (1)

Journal

Check one or more journals to show results from those journals only.

British Journal of Cancer (13)

Choose more journals

Subject Check one or more subjects to show results from those subjects only.

Colorectal cancer (2)
Cancer therapy (1)
Clinical pharmacology (1)
Clinical trials (1)
Combination drug therapy (1)

Date

Choose a date option to show results from those dates only.

Today
Last 7 days
Last 30 days
In the last year
Last 2 years
Last 5 years

Custom date range

Sort by Relevance

Choose a way to sort results.

Relevance
Date — most recent
Date — oldest first

Loading Filters

Showing 1–13 of 13 results

Loading Filters

Amendments and Corrections | 25 November 2008 | Open
Erratum: Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?
- C Massard
- , J-J Voigt
- , A Laplanche
- , S Culine
- , A Lortholary
- , R Bugat
- , C Theodore
- , F Priou
- , M-C Kaminsky
- , T Lesimple
- , X Pivot
- , B Coudert
- , J-Y Douillard
- , Y Merrouche
- & K Fizazi
British Journal of Cancer 99 , 1959–1959

Rights & permissionsfor article Erratum: Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy? . Opens in a new window.
21 November 2013 | Open
First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study
- J-Y Douillard
- , G Ostoros
- , M Cobo
- , T Ciuleanu
- , R McCormack
- , A Webster
- & T Milenkova
British Journal of Cancer 110 , 55–62

Rights & permissionsfor article First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study . Opens in a new window.
1 June 1994
Phase II study of nitrosourea fotemustine as single-drug chemotherapy in poor-prognosis non-small-cell lung cancer
- J-L Pujol
- , A Monnier
- , J Berille
- , M-L Cerrina
- , J-Y Douillard
- , A Rivière
- , A Grandgirard
- , S Gouva
- , J-P Bizzari
- & T Le Chevalier
British Journal of Cancer 69 , 1136–1140

Rights & permissionsfor article Phase II study of nitrosourea fotemustine as single-drug chemotherapy in poor-prognosis non-small-cell lung cancer . Opens in a new window.
17 July 2007 | Open
Phase II study of UFT with leucovorin and irinotecan (TEGAFIRI): first-line therapy for metastatic colorectal cancer
- J-P Delord
- , J Bennouna
- , P Artru
- , H Perrier
- , F Husseini
- , F Desseigne
- , E François
- , R Faroux
- , D Smith
- , P Piedbois
- , H Naman
- , J Y Douillard
- & R Bugat
British Journal of Cancer 97 , 297–301

Rights & permissionsfor article Phase II study of UFT with leucovorin and irinotecan (TEGAFIRI): first-line therapy for metastatic colorectal cancer . Opens in a new window.
11 October 2011 | Open
Health-related quality of life in patients with metastatic colorectal cancer treated with panitumumab in first- or second-line treatment
- L Bennett
- , Z Zhao
- , B Barber
- , X Zhou
- , M Peeters
- , J Zhang
- , F Xu
- , J Wiezorek
- & J-Y Douillard
British Journal of Cancer 105 , 1495–1502

Rights & permissionsfor article Health-related quality of life in patients with metastatic colorectal cancer treated with panitumumab in first- or second-line treatment . Opens in a new window.
25 April 2006 | Open
Vinflunine – an active chemotherapy for treatment of advanced non-small-cell lung cancer previously treated with a platinum-based regimen: results of a phase II study
- J Bennouna
- , J-L Breton
- , J-M Tourani
- , C Ottensmeier
- , M O'Brien
- , P Kosmidis
- , T E Huat
- , M-C Pinel
- , C Colin
- & J-Y Douillard
British Journal of Cancer 94 , 1383–1388

Rights & permissionsfor article Vinflunine – an active chemotherapy for treatment of advanced non-small-cell lung cancer previously treated with a platinum-based regimen: results of a phase II study . Opens in a new window.
15 August 2003 | Open
Summary report of the Standards, Options and Recommendations for the management of patients with non-small-cell lung carcinoma (2000)
- A Depierre
- , J L Lagrange
- , S Theobald
- , P Astoul
- , P Baldeyrou
- , E Bardet
- , B Bazelly
- , J M Bréchot
- , J L Breton
- , J Y Douillard
- , M Grivaux
- , P Jacoulet
- , A Khalil
- , E Lemarié
- , Y Martinet
- , G Massard
- , B Milleron
- , T Molina
- , D Moro-Sibilot
- , M Paesmans
- , J L Pujol
- , E Quoix
- , E Ranfaing
- , A Rivière
- , H Sancho-Garnier
- , P J Souquet
- , D Spaeth
- , A Stœbner-Delbarre
- , L Thiberville
- , E Touboul
- , F Vaylet
- , J M Vergnon
- & V Westeel
British Journal of Cancer 89 , S35–S49

Rights & permissionsfor article Summary report of the Standards, Options and Recommendations for the management of patients with non-small-cell lung carcinoma (2000) . Opens in a new window.
18 April 2006 | Open
Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial
- J Cassidy
- , J-Y Douillard
- , C Twelves
- , J J McKendrick
- , W Scheithauer
- , I Bustová
- , P G Johnston
- , K Lesniewski-Kmak
- , S Jelic
- , G Fountzilas
- , F Coxon
- , E Díaz-Rubio
- , T S Maughan
- , A Malzyner
- , O Bertetto
- , A Beham
- , A Figer
- , P Dufour
- , K K Patel
- , W Cowell
- & L P Garrison
British Journal of Cancer 94 , 1122–1129

Rights & permissionsfor article Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial . Opens in a new window.
1 May 2001 | Open
Combined paclitaxel and gemcitabine as first-line treatment in metastatic non-small cell lung cancer: a multicentre phase II study
- J Y Douillard
- , D Lerouge
- , A Monnier
- , J Bennouna
- , A M Haller
- , X S Sun
- , D Assouline
- , B Grau
- & A Rivière
British Journal of Cancer 84 , 1179–1184

Rights & permissionsfor article Combined paclitaxel and gemcitabine as first-line treatment in metastatic non-small cell lung cancer: a multicentre phase II study . Opens in a new window.
13 December 2005 | Open
‘A phase II study of oral uracil/ftorafur (UFT^®) plus leucovorin combined with oxaliplatin (TEGAFOX) as first-line treatment in patients with metastatic colorectal cancer’
- J Bennouna
- , H Perrier
- , B Paillot
- , F Priou
- , J H Jacob
- , M Hebbar
- , S Bordenave
- , J F Seitz
- , F Cvitkovic
- , E Dorval
- , K Malek
- , D Tonelli
- & J Y Douillard
British Journal of Cancer 94 , 69–73

Rights & permissionsfor article ‘A phase II study of oral uracil/ftorafur (UFT®) plus leucovorin combined with oxaliplatin (TEGAFOX) as first-line treatment in patients with metastatic colorectal cancer’ . Opens in a new window.
18 September 2007 | Open
Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?
- C Massard
- , J-J Voigt
- , A Laplanche
- , S Culine
- , A Lortholary
- , R Bugat
- , C Theodore
- , F Priou
- , M-C Kaminsky
- , T Lesimple
- , X Pivot
- , B Coudert
- , J-Y Douillard
- , Y Merrouche
- & K Fizazi
British Journal of Cancer 97 , 857–861

Rights & permissionsfor article Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy? . Opens in a new window.
8 January 2013 | Open
Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer
- D Cunningham
- , R P W Wong
- , G D'Haens
- , J-Y Douillard
- , J Robertson
- , A M Stone
- & E Van Cutsem
British Journal of Cancer 108 , 493–502

Rights & permissionsfor article Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer . Opens in a new window.
17 November 2009 | Open
Quality-of-life findings from a randomised phase-III study of XELOX vs FOLFOX-6 in metastatic colorectal cancer
- T Conroy
- , M Hebbar
- , J Bennouna
- , M Ducreux
- , M Ychou
- , G Llédo
- , A Adenis
- , R Faroux
- , C Rebischung
- , L Kockler
- & J Y Douillard
British Journal of Cancer 102 , 59–67

Rights & permissionsfor article Quality-of-life findings from a randomised phase-III study of XELOX vs FOLFOX-6 in metastatic colorectal cancer . Opens in a new window.

Nature Research menu

Our Journals

Nature
Nature Communications
Nature Protocols
Scientific Reports
View all journals

Subjects

Biological Sciences
Scientific Community & Society
Earth & Environmental Sciences
Health Sciences
Physical Sciences
View all subjects

Contact us
Authors & Referees
Librarians
Advertisers
Press
About Nature Research

Search

Article search

Advanced search

Quick links

Explore articles by subject
Find a job
Guide to authors
Editorial policies

nature.com sitemap

About us
Press releases
Press office
Contact us

Discover content

Journals A-Z
Articles by subject
Nano
Protocol Exchange
Nature Index

Publish with us

Guide to Authors
Guide to Referees
Editorial policies
Open access
Reprints & permissions

Researcher services

Research data
Language editing
Scientific editing
Nature Masterclasses
Nature Research Academies

Libraries & institutions

Librarian service & tools
Librarian portal
Open research

Advertising & partnerships

Advertising
Partnerships & Services
Media kits
Branded content

Career development

Nature Careers
Nature Conferences
Nature events

Regional websites

Nature China
Nature India
Nature Japan
Nature Korea
Nature Middle East

Refine your results by…

Filters ​

Filter By:

Search

Quick links

Filters